TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8231903

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day conjugated equine oestrogens (CEE) cyclically + 2.5 mg MPA sequentially for the last 12 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 50 micrograms/day transdermal oestradiol cyclically + 2.5 mg MPA sequentially for the last 12 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day CEE continuously + 2.5 mg MPA sequentially for the last 12 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day CEE + 2.5 mg/day MPA continuously
Number of subjects: 90

Group type: COMPARATOR
Intervention: Treatment-free control group
Number of subjects: 90
Study: 3544035

Group type: EXPERIMENTAL
Intervention: Omnipaque 300 (iohexol)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hexabrix 320 (ioxaglate sodium meglumine)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Isopaque Coronar 370 (metrizoate)
Number of subjects: 120
Study: 29269199

Group type: EXPERIMENTAL
Intervention: Mixed lipid emulsion composed of soybean oil, medium chain triglycerides, olive oil, and fish oil
Number of subjects: 230

Group type: COMPARATOR
Intervention: Soybean oil-based lipid emulsion (control)
Number of subjects: 230
Study: 26905919

Group type: COMPARATOR
Intervention: Immediate-release methylphenidate (n=26) thrice daily (10-20 mg per dose)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Atomoxetine (n=26) once daily (0.5-1.2 mg/kg/day)
Number of subjects: 52
Study: 25047046

Group type: EXPERIMENTAL
Intervention: Press needle acupuncture
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Press plaster acupressure
Number of subjects: 75

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 75
Study: 24717936

Group type: EXPERIMENTAL
Intervention: Acute amphetamine administration following a sensitizing dosage regime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 23272658

Group type: EXPERIMENTAL
Intervention: Regadenoson (0.4 mg) during CMR stress imaging
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Regadenoson (0.4 mg) during CMR stress imaging without aminophylline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Regadenoson (0.4 mg) during CMR stress imaging with aminophylline (125 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recovery facilitated with aminophylline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recovery without aminophylline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recovery with aminophylline
Number of subjects: 20
Study: 20669300

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study: 17608869

Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention (8 sessions over 12 weeks)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 186
Study: 16258905

Group type: EXPERIMENTAL
Intervention: Milnacipran (active drug)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 12021741

Group type: EXPERIMENTAL
Intervention: Chiropractic care
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Brief massage treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 23
Study: 10202785

Group type: EXPERIMENTAL
Intervention: 8 month, weekly psychological intervention
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Weekend of support and training in coping skills
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n = 36)
Number of subjects: 30
Study: 8651088

Group type: EXPERIMENTAL
Intervention: Alacepril (50 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 1734740

Group type: EXPERIMENTAL
Intervention: 5% amobarbital solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: saline
Number of subjects: 20
Study: 6381169

Group type: EXPERIMENTAL
Intervention: Rifamycin SV 250 mg intramuscularly and topical b.i.d.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neuramide b.i.d. plus other drugs (antibiotics, polivitamins, analgesics, etc.)
Number of subjects: 60
Study: 31881993

Group type: EXPERIMENTAL
Intervention: Human-animal interaction (HAI) intervention - volunteering at a local animal shelter
Number of subjects: 70

Group type: COMPARATOR
Intervention: Community volunteer condition - volunteering at a community agency of their choice
Number of subjects: 70
Study: 29676689

Group type: EXPERIMENTAL
Intervention: IV acetaminophen 1000 mg/100 ml every 8 hours for 48 hours
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo (100 ml of 0.9% normal saline every 8 hours for 48 hours)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 26930415

Group type: EXPERIMENTAL
Intervention: Active case finding (ACF) with Xpert MTB/RIF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive case finding (PCF)
Number of subjects: 0
Study: 22998596

Group type: EXPERIMENTAL
Intervention: High-volume local anesthesia (≥7.2 mL, four carpules)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low-volume local anesthesia (≤0.9 mL, half a carpule)
Number of subjects: 100
Study: 22287203

Group type: EXPERIMENTAL
Intervention: Supervised therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Uncontrolled exercise therapy
Number of subjects: 22
Study: 20375404

Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine
Number of subjects: 410

Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 410
Study: 17391294

Group type: COMPARATOR
Intervention: ICF modified by a working group (C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICF with systematic lexico‐syntactic readability improvement (B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICF modified by the working group followed by systematic lexico‐syntactic improvement (D)
Number of subjects: 0
Study: 15764686

Group type: EXPERIMENTAL
Intervention: Photo-novella (Laduma)
Number of subjects: 1168
Study: 12040953

Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg orally twice daily for 2 days
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Vitamin C 100 mg orally twice daily for 2 days
Number of subjects: 1005

Group type: COMPARATOR
Intervention: BV-negative group (no treatment)
Number of subjects: 1005
Study: 9462527

Group type: EXPERIMENTAL
Intervention: 60% humidified oxygen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Medical compressed air (room air)
Number of subjects: 40
Study: 8527349

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/ZOK (100-200 mg once daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Atenolol (50-100 mg once daily)
Number of subjects: 24
Study: 1615139

Group type: EXPERIMENTAL
Intervention: L-dopa medication
Number of subjects: 10

Group type: COMPARATOR
Intervention: Withdrawal of L-dopa medication
Number of subjects: 10
Study: 6700850

Group type: EXPERIMENTAL
Intervention: Metronidazole (two-dose perioperative course)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Suction drainage
Number of subjects: 150
Study: 31211324

Group type: EXPERIMENTAL
Intervention: Digoxin pre-treatment
Number of subjects: 6800

Group type: COMPARATOR
Intervention: Placebo during trial
Number of subjects: 6800

Group type: COMPARATOR
Intervention: Randomized comparison (not specified intervention)
Number of subjects: 6800
Study: 29538220

Group type: EXPERIMENTAL
Intervention: Chinese medicine warm compress (CMWC) combined with WHO 3-step analgesic ladder treatment
Number of subjects: 62

Group type: COMPARATOR
Intervention: WHO 3-step analgesic ladder treatment (control group)
Number of subjects: 62
Study: 27548072

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg daily for 6 weeks
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) as add-on therapy
Number of subjects: 89

Group type: COMPARATOR
Intervention: No CPAP (control group)
Number of subjects: 89
Study: 24905241

Group type: EXPERIMENTAL
Intervention: Classroom-based Cognitive Behaviour Therapy (CBT)
Number of subjects: 5030
Study: 22279190

Group type: EXPERIMENTAL
Intervention: Muscle synergies (4 synergies used)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Muscle synergies
Number of subjects: 8
Study: 21046929

Group type: EXPERIMENTAL
Intervention: Fentanyl pectin nasal spray (FPNS)
Number of subjects: 403
Study: 17416261

Group type: EXPERIMENTAL
Intervention: Darunavir-ritonavir 600/100 mg twice daily
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control PIs
Number of subjects: 230
Study: 15702343

Group type: EXPERIMENTAL
Intervention: Swimming with fins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Swimming without fins
Number of subjects: 0
Study: 12162977

Group type: EXPERIMENTAL
Intervention: Forearm tourniquet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Upper arm tourniquet
Number of subjects: 24
Study: 10212733

Group type: EXPERIMENTAL
Intervention: Coping Effectiveness Training (CET) intervention
Number of subjects: 38

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 38
Study: 7619619

Group type: EXPERIMENTAL
Intervention: Iohexol 4.5 mg I/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iohexol 6.75 mg I/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iohexol 9 mg I/ml
Number of subjects: 0
Study: 2617277

Group type: EXPERIMENTAL
Intervention: Clonidine (200 micrograms)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 1273032

Group type: EXPERIMENTAL
Intervention: Talampicillin hydrochloride (125 mg of ampicillin equivalent, four times daily for six days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ampicillin (250 mg, four times daily for six days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Talampicillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 0
Study: 31226323

Group type: EXPERIMENTAL
Intervention: Long-acting reversible contraceptive (LARC) methods
Number of subjects: 2551

Group type: EXPERIMENTAL
Intervention: Implantable contraceptives
Number of subjects: 2551

Group type: EXPERIMENTAL
Intervention: Copper intrauterine device
Number of subjects: 2551

Group type: EXPERIMENTAL
Intervention: Injectable contraceptives (depot medroxyprogesterone acetate)
Number of subjects: 2551

Group type: EXPERIMENTAL
Intervention: Injectable contraceptives (norethisterone enanthate)
Number of subjects: 2551

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 2551
Study: 29076668

Group type: EXPERIMENTAL
Intervention: 6mg dexamethasone in 4 doses 12 hours apart (Group A)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 2 doses 12 hours apart (Group B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both regimens of dexamethasone
Number of subjects: 48
Study: 25741915

Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam administered three times by weekly intervals
Number of subjects: 40

Group type: COMPARATOR
Intervention: 40 mg methylprednisolone acetate administered just once
Number of subjects: 40
Study: 23907544

Group type: EXPERIMENTAL
Intervention: Prospective-memory task with sustained activity in attentional-control areas (anterior prefrontal cortex)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prospective-memory task with transient activity in parietal and ventral brain regions
Number of subjects: 0
Study: 21459214

Group type: EXPERIMENTAL
Intervention: Ranibizumab + prompt laser
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Ranibizumab + deferred laser
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Triamcinolone + prompt laser
Number of subjects: 691

Group type: COMPARATOR
Intervention: Sham + prompt laser
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Ranibizumab groups
Number of subjects: 691
Study: 19238125

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serotonin-norepinephrine reuptake inhibitor (SNRI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Augmentation treatment
Number of subjects: 0
Study: 16931634

Group type: EXPERIMENTAL
Intervention: Peak flow monitoring
Number of subjects: 296

Group type: COMPARATOR
Intervention: Symptom monitoring
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Peak flow monitoring (twice daily or as needed)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 296
Study: 15324523

Group type: EXPERIMENTAL
Intervention: Adjustable dosing (budesonide/formoterol 1 inhalation b.i.d.; stepping up to 2 or 4 inhalations b.i.d. if asthma worsened)
Number of subjects: 4025

Group type: COMPARATOR
Intervention: Fixed dosing (budesonide/formoterol 2 inhalations b.i.d.)
Number of subjects: 4025
Study: 11765145

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost
Number of subjects: 11

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 11
Study: 9246030

Group type: EXPERIMENTAL
Intervention: Doppler group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Forrest group
Number of subjects: 100
Study: 8317785

Group type: EXPERIMENTAL
Intervention: Budesonide (200 micrograms/puff, 2 puffs b.i.d. and 4 puffs b.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (250 micrograms/puff, 2 puffs b.i.d. and 4 puffs b.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (2 puffs b.i.d. and 4 puffs b.i.d.)
Number of subjects: 0
Study: 3015543

Group type: EXPERIMENTAL
Intervention: sequential intermittent polychemotherapy (sq.CT) of 3 different alternating drug combinations given intermittently over 1 year
Number of subjects: 52

Group type: COMPARATOR
Intervention: 4-drug combination chemotherapy (CT) given intermittently over 3 years
Number of subjects: 52
Study: 31486624

Group type: EXPERIMENTAL
Intervention: 10 mL/kg/h rate 5% Dextrose infusion preoperatively for 30 minutes, followed by Ringer's lactate until the end of surgery (Group P)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 10 mL/kg/h rate of Ringer's lactate preoperatively for 30 minutes and 5% Dextrose during the operation (Group I)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Ringer's lactate solution infusion at a rate of 10 mL/kg/h (Group C)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 10 mL/kg/h rate 5% Dextrose infusion preoperatively for 30 minutes (Group P)
Number of subjects: 93
Study: 29723608

Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C
Number of subjects: 680

Group type: COMPARATOR
Intervention: Targeted temperature management at 36°C
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Osborn waves presence
Number of subjects: 680
Study: 26779845

Group type: EXPERIMENTAL
Intervention: OROS MPH
Number of subjects: 237

Group type: COMPARATOR
Intervention: ATX
Number of subjects: 237
Study: 25342703

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine and time-on-task
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Time-on-task
Number of subjects: 12
Study: 23545346

Group type: EXPERIMENTAL
Intervention: 0.2 mg spinal morphine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.3 mg spinal morphine
Number of subjects: 40
Study: 19636702

Group type: EXPERIMENTAL
Intervention: Sequential docetaxel (100 mg/m(2)) followed by epirubicin (75 mg/m(2)) plus cyclophosphamide (700 mg/m(2))
Number of subjects: 756

Group type: COMPARATOR
Intervention: FEC regimen (epirubicin 75 mg/m(2), cyclophosphamide 700 mg/m(2), and 5-fluorouracil 700 mg/m(2))
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Neutropenia requiring administration of granulocyte colony-stimulating factor
Number of subjects: 756
Study: 18363076

Group type: EXPERIMENTAL
Intervention: Internet-delivered, computer-tailored lifestyle intervention targeting saturated fat intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internet-delivered, computer-tailored lifestyle intervention targeting physical activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (waiting list control group)
Number of subjects: 0
Study: 15963377

Group type: EXPERIMENTAL
Intervention: Verbal task (newly designed, no manual responses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual task (similar to conventional line bisection tasks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 12558203

Group type: EXPERIMENTAL
Intervention: Gain-framed video
Number of subjects: 480

Group type: COMPARATOR
Intervention: Loss-framed video
Number of subjects: 480
Study: 10587287

Group type: EXPERIMENTAL
Intervention: Deprenyl 15 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8732386

Group type: EXPERIMENTAL
Intervention: 0.08 ml.kg‐1 Albunex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.22 ml.kg‐1 Albunex
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10 ml albumin
Number of subjects: 0
Study: 1816592

Group type: EXPERIMENTAL
Intervention: Standard intervals of 1-3 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard intervals of 4 seconds or longer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shorter reproduction intervals (1-3 seconds)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer reproduction intervals (4 seconds or longer)
Number of subjects: 0
Study: 6315259

Group type: EXPERIMENTAL
Intervention: Combination of propranolol (160 mg daily) and verapamil (360 mg daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Verapamil (360 mg daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of propranolol and verapamil
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg daily)
Number of subjects: 18
Study: 30444145

Group type: EXPERIMENTAL
Intervention: 50 mg tapentadol
Number of subjects: 68

Group type: COMPARATOR
Intervention: Oxycodone 10 mg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 68
Study: 29262811

Group type: EXPERIMENTAL
Intervention: Nutrition and Culinary in the Kitchen program (3-hour weekly classes for 6 weeks, including hands-on cooking and a market tour)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nutrition and Culinary in the Kitchen program
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (usual activities)
Number of subjects: 80
Study: 26109009

Group type: EXPERIMENTAL
Intervention: Dietary Aloe vera at 4%/kg feed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary Aloe vera at 0.5%/kg feed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary Aloe vera at 2%/kg feed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary Aloe vera at 1%/kg feed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary Aloe vera (various dosages)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary Aloe vera (less than or equal to 1.88, 1.86, and 2.79%/kg feed)
Number of subjects: 0
Study: 23681836

Group type: EXPERIMENTAL
Intervention: Magnesium isoglycyrrhizinate (MI) 100 mg intravenously for 4 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 18
Study: 22962205

Group type: EXPERIMENTAL
Intervention: Project P.A.T.H.S. (Tier 1 Program)
Number of subjects: 4049
Study: 19374293

Group type: EXPERIMENTAL
Intervention: Placental cord drainage
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no placental cord drainage)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 17292646

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: s.c. terbutaline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 20
Study: 15723746

Group type: EXPERIMENTAL
Intervention: Lean System 7 (commercial weight-loss product), 3 capsules twice daily for 8 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo, identical capsules twice daily for 8 weeks
Number of subjects: 47
Study: 11879161

Group type: EXPERIMENTAL
Intervention: Switch from sertraline to imipramine (mean dosage, 221 mg/d)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Switch from imipramine to sertraline (mean dosage, 163 mg/d)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Sertraline treatment
Number of subjects: 168

Group type: COMPARATOR
Intervention: Imipramine treatment
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Switching treatments
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Generalized estimating equation analyses
Number of subjects: 168
Study: 10557525

Group type: EXPERIMENTAL
Intervention: Modified brochure with relatively concrete text and abstract graphics
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Relatively concrete text brochure with concrete graphics
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Original brochure containing abstract text and abstract graphics
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group (no brochure)
Number of subjects: 239
Study: 7798653

Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (1 dose for children, 2 doses for adults)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (2 doses for adults)
Number of subjects: 59
Study: 2157637

Group type: EXPERIMENTAL
Intervention: Pyrogastrone five tablets daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 80
Study: 397016

Group type: EXPERIMENTAL
Intervention: Lidoflazine (120 mg t.i.d. for 9 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31504101

Group type: EXPERIMENTAL
Intervention: SQ-LNS with exogenous phytase
Number of subjects: 30

Group type: COMPARATOR
Intervention: SQ-LNS without exogenous phytase
Number of subjects: 30
Study: 28984580

Group type: EXPERIMENTAL
Intervention: McNair and Kahn Scale
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: McNair and Kahn Scale (5-item version)
Number of subjects: 1307

Group type: EXPERIMENTAL
Intervention: Incidence of aggravation score of CDR
Number of subjects: 1307
Study: 24975503

Group type: EXPERIMENTAL
Intervention: 1-day workshop training for oncologists
Number of subjects: 62

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 62